12/4
08:26 am
enlv
Greenberg Traurig Advises Enlivex in $212M Private Placement
Medium
Report
Greenberg Traurig Advises Enlivex in $212M Private Placement
12/4
08:00 am
enlv
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Medium
Report
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
11/26
08:00 am
enlv
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
Medium
Report
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
11/25
07:31 am
enlv
Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
11/24
11:04 am
enlv
Enlivex Therapeutics (NASDAQ:ENLV) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
High
Report
Enlivex Therapeutics (NASDAQ:ENLV) had its "hold" rating reaffirmed by analysts at D. Boral Capital.
11/24
10:00 am
enlv
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
High
Report
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
11/24
07:55 am
enlv
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
Medium
Report
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
11/24
06:40 am
enlv
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
Medium
Report
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
10/29
08:08 am
enlv
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Low
Report
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
10/28
08:15 am
enlv
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Low
Report
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
10/3
03:35 pm
enlv
Enlivex Therapeutics (NASDAQ:ENLV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Enlivex Therapeutics (NASDAQ:ENLV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
08:15 am
enlv
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Medium
Report
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
9/26
08:05 am
enlv
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Medium
Report
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
9/14
10:27 am
enlv
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely? [Yahoo! Finance]
Low
Report
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely? [Yahoo! Finance]
9/12
08:03 am
enlv
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Low
Report
Enlivex Therapeutics (NASDAQ:ENLV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
9/11
08:21 am
enlv
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results [Yahoo! Finance]
Low
Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results [Yahoo! Finance]
9/11
08:00 am
enlv
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Medium
Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
9/9
08:28 am
enlv
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis [Yahoo! Finance]
Neutral
Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis [Yahoo! Finance]
9/9
08:00 am
enlv
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Low
Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis